Track topics on Twitter Track topics that are important to you
Golimumab Methotrexate Psoriatic Arthritis PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Golimumab Methotrexate Psoriatic Arthritis articles that have been published worldwide.
We have published hundreds of Golimumab Methotrexate Psoriatic Arthritis news stories on BioPortfolio along with dozens of Golimumab Methotrexate Psoriatic Arthritis Clinical Trials and PubMed Articles about Golimumab Methotrexate Psoriatic Arthritis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Golimumab Methotrexate Psoriatic Arthritis Companies in our database. You can also find out about relevant Golimumab Methotrexate Psoriatic Arthritis Drugs and Medications on this site too.
Recently, research has been focused on the identification of predictors of response to treatment in patients with active psoriatic arthritis (PsA). The objective of this study was to develop a model to predict the clinical response at 6 months in patients with PsA starting the anti-tumour necrosis factor-α golimumab.
We read with interest, the article on 'Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase 3 Trial' by Philip J. Mease et al.  The failure of the combination group to better outcomes than etanercept monotherapy was a big surprise. Certain clarifications may help us understand the outcome, specifically with regard to key components of composite scores. This article is protected by copyright. All rights reserved.
To evaluate the probability of achieving Clinical Disease Activity for Psoriatic Arthritis (cDAPSA) treatment targets of remission (REM) or low disease activity (LDA) with apremilast based on disease activity categories and corresponding responses in arthritis and other domains of psoriatic arthritis (PsA) not included in cDAPSA.
Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate.
To evaluate the long-term efficacy and safety of maintaining baricitinib monotherapy in patients with active rheumatoid arthritis (RA) originally treated with baricitinib monotherapy or switched from methotrexate (MTX) or the combination of baricitinib plus MTX to baricitinib monotherapy.
We evaluated the psychometric properties of three patient-reported outcomes (PROMs) to assess the physical function in psoriatic arthritis (PsA).
To (1) determine the reliability and validity of the Bristol Rheumatoid Arthritis Fatigue scale (BRAF-NRS) in patients with psoriatic arthritis (PsA) and (2) examine possible clinical associations of worse fatigue in PsA.
To analyse the internal consistency of an adaption of the methotrexate intolerance severity score (MISS); and to describe and compare the level of methotrexate intolerance evaluated by the MISS in Danish children with juvenile idiopathic arthritis (JIA) or acute lymphoblastic leukaemia (ALL), treated with low-dose methotrexate (MTX).
Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intra-patient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this ...
Psoriatic arthritis (PsA) is an immune-mediated systemic inflammatory disorder with heterogeneous clinical features. Treatment for PsA has progressed rapidly, especially over the past two decades. Herein we review relevant studies and key developments in treatment options for PsA from the past 5 years.
To provide the first direct comparison of patient-reported outcomes (PROs) following treatment with tofacitinib monotherapy versus tofacitinib or adalimumab (ADA) in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA) with inadequate response to MTX (MTX-IR).
Adiposity is prevalent among patients with psoriatic arthritis (PsA). However, the temporal relation is unclear. We investigated whether adiposity and body fat distribution may be related to the risk of developing PsA, and whether physical activity could modify the possible risk.
Non-alcoholic fatty liver disease (NAFLD), potentially evolving into liver fibrosis (LF), is frequent in psoriasis (PsO), but data in psoriatic arthritis (PsA) are lacking. Our study aimed to investigate the prevalence of NALFD and LF in PsA/PsO and the contribution of arthritis in their onset.
: Treatment of rheumatic diseases has been greatly advanced by the introduction of biological molecular-targeted therapies. However, owing to their high heterogeneity at the molecular and clinical levels, treatment of rheumatic diseases can often be challenging. Hence, it especially important to select the most optimal targeted therapy for individual patients. There are ten biologics available for the treatment of psoriatic arthritis; however, how each of these can be used most effectively is unclear.: We c...
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to biologics, is effective in the management of treatment resistant disease, and is reported to improve enthesitis, dactylitis, and radiographic progression. Tofacitinib is also associated with an increased risk of ...
The TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) study was the first strategy trial in psoriatic arthritis using an early treat-to-target strategy to improve clinical outcomes. The current study aimed to review a cohort of patients who had completed TICOPA to judge if the clinical advantage gained by participants in the tight control (TC) arm was sustained, and to explore subsequent therapy.
Information about the pre-diagnosis period in psoriatic arthritis (PsA) is limited. We compared health care utilization related to musculoskeletal issues during a 5-year period prior to the diagnosis of PsA versus subjects with no prior inflammatory arthritis within a primary care setting.
Although the frequency of metabolic syndrome has been studied separately in psoriasis, psoriatic arthritis (PsA), and rheumatoid arthritis (RA) patients, there is no study that compares the prevalence of metabolic syndrome in all three diseases. The purpose of this study is to evaluate the relationship between metabolic syndrome (MetS) and chronic low-grade inflammatory diseases, and to determine the frequency of MetS and insulin resistance in psoriasis and PsA as compared to RA.
To assess the educational needs of people with ankylosing spondylitis (AS) and psoriatic arthritis (PsA), test differences across patient subgroups and identify factors independently associated with their educational needs.
To compare the risk of serious infections between the TNF inhibitor (TNFi) plus methotrexate (MTX) versus triple therapy among RA patients in a real-world setting.
Screening psoriasis patients for psoriatic arthritis (PsA) is intended to identify patients at earlier stages of the disease. Early treatment is expected to slow disease progression and delay the need for biologic therapy. This paper determines the cost-effectiveness of screening for PsA in patients with psoriasis in Canada.
The aim of the study is to establish the features of the clinical course of psoriatic arthritis in children. 83 patients with psoriatic arthritis (PSA) were examined. The terms of formation of articular and skin syndromes in PSA in children, as well as options for the onset and height of the disease and features of the course in childhood were revealed. Based on the results of the study, it should be concluded that, in contrast to the literature data, the majority of patients with PSA disease debut falls on...
Meteorin-like(IL-41), is a novel cytokine that is thought to be immunoregulatory and is highly expressed in psoriatic skin. We investigated IL-41 protein expression in synovial tissue in RA(Rheumatoid Arthritis), PsA(Psoriatic Arthritis) and OA(Osteoarthritis) patients and evaluated IL-41 production from healthy enthesis samples, as the enthesis represent the primary inflammatory lesion in PsA. IL-41 was measured in synovial fluid from PsA, RA and OA patients. Synovial biopsies were stained for IL-41 by imm...